CA2933398C - Biomarkers and methods relating to alzheimer's disease - Google Patents
Biomarkers and methods relating to alzheimer's disease Download PDFInfo
- Publication number
- CA2933398C CA2933398C CA2933398A CA2933398A CA2933398C CA 2933398 C CA2933398 C CA 2933398C CA 2933398 A CA2933398 A CA 2933398A CA 2933398 A CA2933398 A CA 2933398A CA 2933398 C CA2933398 C CA 2933398C
- Authority
- CA
- Canada
- Prior art keywords
- markers
- disease
- protein
- subject
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322094.2A GB201322094D0 (en) | 2013-12-13 | 2013-12-13 | Methods and compositions relating to alzheimers disease |
| GB1322094.2 | 2013-12-13 | ||
| PCT/GB2014/053692 WO2015087087A1 (en) | 2013-12-13 | 2014-12-12 | Biomarkers and methods relating to alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2933398A1 CA2933398A1 (en) | 2015-06-18 |
| CA2933398C true CA2933398C (en) | 2023-02-14 |
Family
ID=50030903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2933398A Active CA2933398C (en) | 2013-12-13 | 2014-12-12 | Biomarkers and methods relating to alzheimer's disease |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12345717B2 (enExample) |
| EP (1) | EP3080609B1 (enExample) |
| JP (1) | JP6803230B2 (enExample) |
| CA (1) | CA2933398C (enExample) |
| GB (1) | GB201322094D0 (enExample) |
| WO (1) | WO2015087087A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201504432D0 (en) | 2015-03-17 | 2015-04-29 | Electrophoretics Ltd | Materials and methods for diagnosis and treatment of alzheimers disease |
| EP3242134A1 (en) * | 2016-05-04 | 2017-11-08 | Euroimmun Medizinische Labordiagnostika AG | Assay for the diagnosis of a neurological disease |
| CN109791139A (zh) * | 2016-08-09 | 2019-05-21 | 大塚制药株式会社 | 使用尿液生物标记的阿兹海默氏症的辅助诊断方法 |
| CN110603550A (zh) * | 2016-12-13 | 2019-12-20 | 阿克利互动实验室公司 | 利用导航任务识别生物标志物和利用导航任务进行治疗的平台 |
| WO2019012671A1 (ja) * | 2017-07-13 | 2019-01-17 | 株式会社Ｍｃｂｉ | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 |
| AU2018359624A1 (en) * | 2017-10-31 | 2020-04-30 | Ge Healthcare Limited | Medical system for diagnosing cognitive disease pathology and/or outcome |
| GB201814807D0 (en) * | 2018-09-12 | 2018-10-24 | Univ Newcastle | Dementia Biomarkers |
| SG11202106410VA (en) * | 2019-01-09 | 2021-07-29 | Univ Washington | Multiplexed assay and methods of use thereof |
| US11860170B2 (en) * | 2019-05-16 | 2024-01-02 | Procisedx Inc. | Assay method for the detection of VCAM-1 and alpha-2-macroglobulin in blood |
| US11621087B2 (en) * | 2019-09-24 | 2023-04-04 | International Business Machines Corporation | Machine learning for amyloid and tau pathology prediction |
| EP4051812A1 (en) * | 2019-10-28 | 2022-09-07 | AgenT | Biomarkers and uses thereof for diagnosing the silent phase of alzheimer's disease |
| KR20230004597A (ko) * | 2020-04-14 | 2023-01-06 | 주식회사 지뉴브 | 신경퇴행성질환 치료제에 대한 반응을 평가하기 위한 방법 및 조성물 |
| EP4237857A1 (en) * | 2020-10-30 | 2023-09-06 | Baseline Global, Inc. | Methods, systems, and kits for prediction, detection, monitoring, and treatment of alzheimer's disease |
| US20220260559A1 (en) * | 2020-11-04 | 2022-08-18 | Seer, Inc. | Biomarkers for diagnosing alzheimer's disease |
| CN115066615A (zh) * | 2020-12-28 | 2022-09-16 | 株式会社Mcbi | 判定辅助信息生成方法、判定辅助信息生成系统以及信息处理装置 |
| WO2022192019A1 (en) * | 2021-03-08 | 2022-09-15 | The Children's Medical Center Corporation | Methods for diagnosis and treatment of alzheimer's disease |
| CN115612728A (zh) * | 2021-07-16 | 2023-01-17 | 深圳先进技术研究院 | 一种神经退行性疾病标志物及其应用 |
| CN114705866A (zh) * | 2022-03-14 | 2022-07-05 | 上海市精神卫生中心（上海市心理咨询培训中心） | 基于血液的遗忘型轻度认知损害早期诊断外周血蛋白标志物、应用及其医疗辅助诊断系统 |
| EP4549945A1 (en) * | 2022-06-28 | 2025-05-07 | Mcbi Inc. | Assessment-supporting information generating method, assessment-supporting information generating system, and information processing device |
| WO2024195825A1 (ja) * | 2023-03-22 | 2024-09-26 | 味の素株式会社 | 血中メタボロームによる脳萎縮の評価方法 |
| CN116790745A (zh) * | 2023-07-03 | 2023-09-22 | 复旦大学 | 阿尔茨海默病临床前期疾病转化的标志物及其筛选方法 |
| WO2025057945A1 (ja) * | 2023-09-11 | 2025-03-20 | 国立大学法人三重大学 | 対象が脳アミロイド血管症を有するかを判定するための方法、アルツハイマー病に対する抗アミロイドβ抗体による治療の副作用のリスクまたは存在を判定するための方法、およびアルツハイマー病に対する抗アミロイドβ抗体による治療の対象を選択するための方法、ならびにそのための組成物およびキット |
| CN117538545B (zh) * | 2024-01-09 | 2024-07-05 | 上海众启生物科技有限公司 | 一种用于阿尔茨海默症检测的蛋白抗原组合及应用 |
| WO2025168038A1 (en) * | 2024-02-07 | 2025-08-14 | Kunming Institute Of Zoology, Chinese Academy Of Sciences | Methods and compositions for ameliorating impairment of regenerative and cognitive function |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| JP2005510722A (ja) * | 2001-11-23 | 2005-04-21 | シン．クス ファーマ、インコーポレイテッド | アルツハイマー病を予測するｐｅｄｆバイオポリマーマーカー |
| CA2745998C (en) | 2002-08-23 | 2013-11-26 | Bayer Schering Pharma Aktiengesellschaft | Biomarkers for diagnosing alzheimer's disease |
| US7598049B2 (en) * | 2003-11-19 | 2009-10-06 | Satoris, Inc. | Methods for diagnosis of Alzheimer's Disease in blood samples |
| GB0421639D0 (en) * | 2004-09-29 | 2004-10-27 | Proteome Sciences Plc | Methods and compositions relating to alzheimer's disease |
| DE102010026238B4 (de) * | 2010-06-29 | 2012-08-16 | Schuberth Gmbh | Schutzhelm und Tragkorb für einen Schutzhelm |
-
2013
- 2013-12-13 GB GBGB1322094.2A patent/GB201322094D0/en not_active Ceased
-
2014
- 2014-12-12 EP EP14830849.7A patent/EP3080609B1/en active Active
- 2014-12-12 US US15/104,149 patent/US12345717B2/en active Active
- 2014-12-12 CA CA2933398A patent/CA2933398C/en active Active
- 2014-12-12 JP JP2016538603A patent/JP6803230B2/ja active Active
- 2014-12-12 WO PCT/GB2014/053692 patent/WO2015087087A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US12345717B2 (en) | 2025-07-01 |
| US20170219611A1 (en) | 2017-08-03 |
| GB201322094D0 (en) | 2014-01-29 |
| JP2017500562A (ja) | 2017-01-05 |
| CA2933398A1 (en) | 2015-06-18 |
| EP3080609A1 (en) | 2016-10-19 |
| EP3080609B1 (en) | 2021-05-05 |
| JP6803230B2 (ja) | 2020-12-23 |
| WO2015087087A1 (en) | 2015-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2933398C (en) | Biomarkers and methods relating to alzheimer's disease | |
| US7897361B2 (en) | Methods of diagnosing Alzheimer's disease | |
| Spellman et al. | Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF | |
| KR20170132318A (ko) | 인지 저하의 위험을 예측하는 방법 | |
| JP2026016513A (ja) | アルツハイマー病を判定するためのタンパク質マーカー | |
| US20230333121A1 (en) | Methods and compositions relating to biomarkers for neurodegenerative diseases | |
| WO2011092504A2 (en) | Biomarkers | |
| US20250329454A1 (en) | Diagnostic indices for neurodegenerative conditions | |
| Devanarayan et al. | Plasma pTau181 enhances the prediction of future clinical decline in amyloid‐positive mild cognitive impairment | |
| AU2011253636B2 (en) | Methods and compositions relating to alzheimer's disease | |
| Santamarina et al. | Extracellular vesicle proteomics identifies novel blood biomarkers for the early diagnosis of status epilepticus | |
| CA3089120A1 (en) | Methods of treating spinal muscular atrophy | |
| Paganelli | Determinants of platelet activation in Alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20191212 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241206 |